ANTX — AN2 Therapeutics Share News
0.000.00%
Last trade - 00:00AN2 Therapeutics plummets as co to pause enrollment in lung disease study
AN2 Therapeutics to pause lung disease study enrollment (updated)
AN2 Therapeutics to pause lung disease study enrollment
Brief: AN2 To Voluntarily Pause Enrollment In Phase 3 Part Of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole
Brief: An2 Therapeutics Inc - License Enables Advancement Of An2-502998
Brief: AN2 Therapeutics Signs Grant Agreement To Discover Novel, Boron Based Therapies For Tuberculosis And Malaria
Brief: An2 Therapeutics Commences Phase 3 Part Of Phase 2/3 Clinical Trial Evaluating Epetraborole For Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
Brief: An2 Therapeutics Announces Pricing Of $70.0 Million Underwritten Offering Of Common Stock
Brief: AN2 Therapeutics Q2 net income USD -15.804 million
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Brief: AN2 Therapeutics Reports First Quarter 2023 Financial Results And Recent Highlights
Brief: AN2 Therapeutics Q1 loss from operations USD 16.039 million
Brief: An2 Therapeutics Files For Mixed Shelf Of Up To $300 Million - SEC Filing
U.S. RESEARCH ROUNDUP-Globus Medical, Philip Morris, Vail Resorts
Brief: AN2 Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results And Recent Highlights
U.S. RESEARCH ROUNDUP-Coherent, Huntington Ingalls Industries, Spirit Aerosystems Holdings
Brief: An2 Therapeutics Reports Third Quarter 2022 Financial Results
Brief: An2 Therapeutics Provides Update On Epetraborole Ex-U.S. Development Plan In Treatment-Refractory Mac Lung Disease
Brief: Nih Awards Contract To An2 Therapeutics Valued At $17.8 Mln